PL2480546T3 - Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A - Google Patents

Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A

Info

Publication number
PL2480546T3
PL2480546T3 PL10760968T PL10760968T PL2480546T3 PL 2480546 T3 PL2480546 T3 PL 2480546T3 PL 10760968 T PL10760968 T PL 10760968T PL 10760968 T PL10760968 T PL 10760968T PL 2480546 T3 PL2480546 T3 PL 2480546T3
Authority
PL
Poland
Prior art keywords
imidazopyridine
phosphodiesterase
inhibitors
imidazopyrimidine derivatives
imidazopyrimidine
Prior art date
Application number
PL10760968T
Other languages
English (en)
Inventor
Daniela Alberati
Sánchez Rubén Alvarez
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Markus Rudolph
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2480546T3 publication Critical patent/PL2480546T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL10760968T 2009-09-24 2010-09-21 Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A PL2480546T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09171253 2009-09-24
EP10760968.7A EP2480546B1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors
PCT/EP2010/063830 WO2011036127A1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors

Publications (1)

Publication Number Publication Date
PL2480546T3 true PL2480546T3 (pl) 2015-05-29

Family

ID=43416552

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10760968T PL2480546T3 (pl) 2009-09-24 2010-09-21 Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A

Country Status (23)

Country Link
US (2) US8017604B2 (pl)
EP (1) EP2480546B1 (pl)
JP (1) JP5629322B2 (pl)
KR (1) KR101426624B1 (pl)
CN (1) CN102548991B (pl)
AR (1) AR078437A1 (pl)
BR (1) BR112012006531A2 (pl)
CA (1) CA2770087C (pl)
CL (1) CL2012000708A1 (pl)
CY (1) CY1116120T1 (pl)
DK (1) DK2480546T3 (pl)
ES (1) ES2530884T3 (pl)
HR (1) HRP20150345T1 (pl)
IL (1) IL218032A (pl)
MX (1) MX2012003469A (pl)
PE (1) PE20121438A1 (pl)
PH (1) PH12012500355A1 (pl)
PL (1) PL2480546T3 (pl)
PT (1) PT2480546E (pl)
RU (1) RU2502737C2 (pl)
SI (1) SI2480546T1 (pl)
TW (1) TWI402268B (pl)
WO (1) WO2011036127A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
KR20140048079A (ko) 2011-02-01 2014-04-23 교와 핫꼬 기린 가부시키가이샤 축환 복소환 유도체
WO2012112946A1 (en) 2011-02-18 2012-08-23 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
EP2574607A1 (en) * 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
BR112014006248A2 (pt) * 2011-09-19 2017-04-11 Hoffmann La Roche compostos de triazolopiridina como inibidores de pde10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
EP2951176A1 (en) * 2013-01-31 2015-12-09 F. Hoffmann-La Roche AG Radiolabeled compounds
TR201904614T4 (en) 2013-02-27 2019-05-21 Mochida Pharm Co Ltd Novel pyrazole derivative.
RU2015147450A (ru) 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
CN105164126B (zh) * 2013-04-30 2017-05-31 豪夫迈·罗氏有限公司 吡唑酰胺的Pd‑催化偶联
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
KR101770532B1 (ko) 2013-09-26 2017-08-22 에프. 호프만-라 로슈 아게 이미징 수단으로서의 이미다조[1,2-a]피리딘-7-아민
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
IL264955B (en) 2016-09-02 2022-06-01 Ironwood Pharmaceuticals Inc Fused bicyclic sgc stimulators
CN113698406A (zh) * 2021-08-30 2021-11-26 成都药明康德新药开发有限公司 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法
UY40979A (es) * 2023-11-21 2025-06-30 Novartis Ag Iimidazoarenos sustituidos, composición farmacéutica que los comprende y método para la formación de un complejo que los comprende

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610697B1 (en) * 1999-11-10 2003-08-26 Ortho-Mcneil Pharmaceutical, Inc. Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
ES2393333T3 (es) * 2002-07-12 2012-12-20 Astellas Pharma Inc. Derivado de N-fenil-(2R,5S)dimetilpiperazina
EP1570847B1 (en) * 2002-12-03 2012-04-25 Kyorin Pharmaceutical Co., Ltd. Phosphodiesterase 10a inhibitors for use in the treatment of parkinson's disease, huntington's disease and schizophrenia
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
US7998974B2 (en) * 2005-03-03 2011-08-16 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
KR101062583B1 (ko) * 2006-01-17 2011-09-06 에프. 호프만-라 로슈 아게 Gaba 수용체에 의해 알츠하이머병의 치료에 유용한아릴-아이속사졸-4-일-이미다조[1,2-a]피리딘
MX2008010668A (es) 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
ES2530884T3 (es) 2015-03-06
SI2480546T1 (sl) 2015-03-31
RU2012113128A (ru) 2013-11-10
DK2480546T3 (en) 2015-02-02
CA2770087C (en) 2014-09-09
KR20120068943A (ko) 2012-06-27
JP2013505911A (ja) 2013-02-21
MX2012003469A (es) 2012-04-19
IL218032A0 (en) 2012-04-30
EP2480546A1 (en) 2012-08-01
CA2770087A1 (en) 2011-03-31
US20110071128A1 (en) 2011-03-24
AR078437A1 (es) 2011-11-09
TW201116530A (en) 2011-05-16
JP5629322B2 (ja) 2014-11-19
US20110294779A1 (en) 2011-12-01
CN102548991B (zh) 2015-03-25
IL218032A (en) 2014-06-30
CL2012000708A1 (es) 2012-09-07
AU2010299927A1 (en) 2012-03-15
PT2480546E (pt) 2015-02-09
PE20121438A1 (es) 2012-10-26
TWI402268B (zh) 2013-07-21
HRP20150345T1 (hr) 2015-05-08
KR101426624B1 (ko) 2014-08-05
CY1116120T1 (el) 2017-02-08
US8263584B2 (en) 2012-09-11
BR112012006531A2 (pt) 2016-11-22
EP2480546B1 (en) 2014-12-31
US8017604B2 (en) 2011-09-13
PH12012500355A1 (en) 2019-11-29
CN102548991A (zh) 2012-07-04
WO2011036127A1 (en) 2011-03-31
RU2502737C2 (ru) 2013-12-27

Similar Documents

Publication Publication Date Title
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
PL2456444T3 (pl) Pochodne adeniny jako inhibitory PI3K
IL218032A0 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
LTC2231667I2 (lt) Beta-laktamazės inhibitoriai
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
ZA201203326B (en) Imidazopyridine derivatives as jak inhibitors
PL2927213T3 (pl) Pochodne piperydynonu jako inhibitory MDM2 do leczenia nowotworu
SMT201600104B (it) Inibitore di bromodominio benzodiazepinico
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0814065A2 (pt) Derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
EP2391627A4 (en) BICYCLIC PYRAZOLO HETEROCYCLES
BR112012008108A2 (pt) derivados de xantina substituídos
DK2376490T3 (da) Imidazopyridinforbindelser
PT2536730E (pt) Compostos pirrolopirimidina enquanto inibidores de cdk4/6
PL2649076T3 (pl) Makrocyklowe inhibitory wirusów Flaviviridae
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
IL212285A0 (en) Azaindole derivatives
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
BRPI0914301A2 (pt) derivados de pirimidin-4-ona substituída
GB201016880D0 (en) Phosphodiesterase inhibitors
ATE506358T1 (de) 2-benzylpyridazinonderivate als met-kinasehemmer
ATE545417T1 (de) Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
DK2114951T3 (da) Hidtil ukendte phosphodiesterase-inhibitorer
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
PL3070091T3 (pl) Pochodne benzodioksolu jako inhibitory fosfodiesterazy